Compare Fiverr International Ltd (FVRR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs ResMed Inc. — how do they compare? Fiverr International Ltd trades at $8.66 (market cap $314.57M), while ResMed Inc. trades at $223.8 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 103.7× Fiverr International Ltd's market cap, and ResMed Inc. pays a 1.17% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | RMD | |
|---|---|---|
Market Cap | $314.57M | $32.61B |
Sector | Industrials | Health |
52-Week High | $26.67 | $293.73 |
52-Week Low | $8.75 | $182.82 |
Enterprise Value | $66.95M | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $9.09, down 3.5% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation metrics with P/E of 10.8 and P/S of 0.77, while revenue grew to $430.91M in 2025. However, Q2 2026 results disappointed with revenue declining 10% year-over-year as AI disruption pressures the freelance marketplace business model. Analyst sentiment remains cautious with 76% hold ratings despite a $10.70 consensus price target suggesting 18% upside potential.
Fiverr faces significant headwinds from AI competition compressing demand for lower-value freelance work, though current valuations appear discounted. The company maintains strong gross margins at 82% and positive net income, but growth sustainability concerns persist. Near-term catalysts include Q3 earnings and AI strategy execution, while risks center on market share erosion and guidance revisions. The stock trades near support levels with mixed technical indicators.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
